Teicoplanin
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Teicoplanin: From Serious Gram-Positive Infections to Bacterial Arthritis
One-Sentence Summary
Teicoplanin is a glycopeptide antibiotic established for the treatment of serious Gram-positive bacterial infections, including bone and joint infections, endocarditis and bacteraemia. The TxGNN model predicts it may also be effective for Bacterial Arthritis (septic/pyogenic arthritis), a prediction currently supported by 20 publications but no dedicated clinical trials. Because septic arthritis is already a recognised subset of Gram-positive bone and joint infection, this finding largely confirms an existing therapeutic role rather than revealing a genuinely novel indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No UK marketing-authorisation text available; established use is for serious Gram-positive bacterial infections (bone/joint infections, endocarditis, bacteraemia) |
| Predicted New Indication | Bacterial Arthritis (septic/pyogenic arthritis) |
| TxGNN Prediction Score | 94.25% |
| Evidence Level | L3 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for teicoplanin is not available from DrugBank in this Evidence Pack. Based on the supporting literature, teicoplanin is a glycopeptide antibiotic that inhibits cell-wall synthesis in Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). This mechanism underlies its long-established use in serious Gram-positive infections such as bone and joint infections, endocarditis and bacteraemia.
Bacterial arthritis (septic/pyogenic arthritis) is typically caused by Gram-positive organisms, most commonly S. aureus, and is clinically classified alongside osteomyelitis as a bone and joint infection. Multiple cohort studies and case series in the evidence pack (e.g., Weinberg 1993; LeFrock 1992; Peeters 2016; Bibler 1987) directly document teicoplanin use in septic/pyogenic arthritis with reported clinical cure. The TxGNN prediction therefore reflects an indication that already sits within teicoplanin’s recognised spectrum of use, rather than a mechanistically novel repurposing signal.
This is reinforced by dosing literature specifically addressing septic arthritis: Grüneberg (1997) notes that septic arthritis is one of only three clinical situations warranting a higher maintenance dose (12 mg/kg/day) versus the standard regimen, indicating that clinicians have long treated this specific presentation with teicoplanin using tailored dosing.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8351549 | 1993 | Cohort (community-based trial) | Southern Medical Journal | Once-daily teicoplanin (~10.1 mg/kg) treated 66 patients with Gram-positive osteomyelitis and septic arthritis; all 60 recovered isolates were teicoplanin-sensitive |
| 11131961 | 2000 | Review | Journal of Chemotherapy | Reviews teicoplanin dosing for endocarditis, bacteraemia and bone/joint infections; notes advantages over vancomycin (longer half-life, lower nephrotoxicity) |
| 27809799 | 2016 | Cohort | BMC Infectious Diseases | Teicoplanin-based therapy (including subcutaneous route) evaluated for tolerance and efficacy in S. aureus bone and joint infection |
| 1381644 | 1992 | Cohort (multicentre cooperative study) | European Journal of Surgery Supplement | US multicentre study of once-daily IV/IM teicoplanin in 90 evaluable patients with Gram-positive bone/joint infections (acute and chronic osteomyelitis) |
| 2952062 | 1987 | Case series | Antimicrobial Agents and Chemotherapy | 19 patients with serious Gram-positive infections, including pyogenic arthritis, treated with teicoplanin; 8/13 evaluable infections clinically cured |
| 12481488 | 2002 | Retrospective cohort | Medicina (Buenos Aires) | Retrospective review of 89 episodes of MRSA bone/joint infection, including 10 cases of septic arthritis, treated with teicoplanin plus surgery |
| 17825421 | 2007 | Cohort/PK study | The Journal of Infection | Investigated whether standard teicoplanin doses achieve target trough levels (≥20 mg/L) in musculoskeletal infection patients |
| 2140111 | 1990 | Case series | Journal of Antimicrobial Chemotherapy | 33 patients with prosthetic infection, osteomyelitis, soft-tissue infection and septic arthritis treated with teicoplanin |
| 9474479 | 1997 | Review | Drugs | Identifies teicoplanin/vancomycin as most reliable agents for serious Gram-positive infection; specifies higher maintenance dose (12 mg/kg/day) for septic arthritis |
| 28900682 | 2017 | Review | Current Topics in Microbiology and Immunology | Broad review of S. aureus treatment across skin, bone, bloodstream and respiratory infections, including glycopeptide therapy |
UK Market Information
Teicoplanin currently holds no UK marketing authorisation on file in this Evidence Pack and is not marketed in the UK (0 licences recorded). No product name, dosage form or licensed indication text is available for citation. Any UK use would need to be confirmed against the current MHRA product register and Summary of Product Characteristics (SmPC), and considered against BNF classification for parenteral glycopeptide antibacterials.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Decades of cohort studies and case series consistently support teicoplanin’s efficacy in Gram-positive bone, joint and septic arthritis infections (Evidence Level L3), but no randomised controlled trial specifically targets bacterial arthritis as a standalone indication, and the drug currently has no UK marketing authorisation.
To proceed, the following is needed:
- Confirmed mechanism-of-action (MOA) data from DrugBank or the manufacturer’s SmPC
- SmPC warnings, contraindications and drug-interaction data (currently unavailable — flagged as blocking in the source data)
- Verification of current UK marketing/import status if clinical use is being considered
- A formal comparison against existing glycopeptide dosing guidance for septic arthritis (e.g., the 12 mg/kg/day regimen noted in the literature) before any local protocol adoption
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.